Desvenlafaxine Tablet, Film Coated, Extended Release
Product Images NDC 50090-4806

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 50090-4806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem-structure.jpg (Chem Structure)

Chemical structure diagram depicting the active ingredient desvenlafaxine, including its associated molecular components and hydration state as shown.*

FDA Label Image

Figure1.jpg (Figure1)

A forest plot chart showing the geometric mean ratio (90% confidence interval) of Desvenlafaxine pharmacokinetic parameters (Cmax and AUC) relative to reference values across categories of renal impairment, hepatic impairment, and population subgroups by gender and age. The x-axis represents change relative to reference, ranging from 0.5 to 3.5, and the chart includes data points with error bars for mild, moderate, severe, and End Stage Renal Disease (ESRD), as well as mild, moderate, and severe hepatic impairment, female gender, and age groups 65-75 years and over 75 years.*

FDA Label Image

Figure2.jpg (Figure2)

A forest plot showing the geometric mean ratio with 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of Desvenlafaxine in presence of the CYP3A4 inhibitor Ketoconazole. The chart plots values relative to reference, indicating an increase in exposure with Ketoconazole, with Cmax around 1.08 and AUC around 1.43.*

FDA Label Image

Figure3.jpg (Figure3)

A forest plot graph showing the geometric mean ratios (with 90% confidence intervals) for pharmacokinetic parameters Cmax and AUC of various CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4 substrates when interacting with Desvenlafaxine (Pristiq) at doses of 50 mg, 100 mg, and 400 mg. Substrates include Desipramine, Midazolam, Tamoxifen, and Aripiprazole, with relative changes plotted on a horizontal axis ranging from 0.50 to 2.5.*

FDA Label Image

Figure4.jpg (Figure4)

A line chart comparing the estimated proportion of patients with relapse over time (days from randomization) between Desvenlafaxine 50 mg and placebo. The x-axis represents time in days up to about 200, and the y-axis shows the proportion of patients relapsing, reaching up to 50%. The graph includes two lines: a solid line for Desvenlafaxine 50 mg with a lower relapse rate, and a dashed line for placebo with a higher relapse rate over time.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph depicting the estimated proportion of patients with relapse over time (days from randomization) for Desvenlafaxine versus Placebo. The y-axis represents the estimated proportion with relapse, and the x-axis represents time in days up to 200. Two lines compare relapse rates: a solid line for Desvenlafaxine and a dashed line for Placebo.*

FDA Label Image

Label Image (Lbl500904806)

Desvenlafaxine 50 mg extended-release film-coated tablets in a blister pack. The label shows the product name, strength, dosage form, and storage instructions (store at 68 to 77 degrees F). The package contains 30 tablets. The labeler is A-S Medication Solutions, and the product NDC is 50090-4806-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.